CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-02). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 1947 · Search date 2026-08-02 · Methodology v0.6

Hyaluronic acid filler,
does it really help with Visible correction and durability of moderate-to-severe nasolabial folds?

30-Second Summary
C
Evidence Grade C · 55 · Safety warning
The gel occupies volume and a specific product improved folds at 24 weeks, but universal durability evidence is limited
Pain, swelling, bruising, and firmness are common. Serious vascular complications were too uncommon in randomized trials to estimate frequency; postmarketing reports are the basis. Literature estimates vascular occlusion at about 1 in 2,000 to 1 in 10,000 (0.05% to 0.01%), with some hyaluronic-acid filler surveys around 3 to 9 per 10,000. Filler-related blindness is estimated around 1 in 100,000 (0.001%). Intravascular injection can cause skin necrosis, blindness, or stroke. Because spontaneous reports are incomplete and denominators uncertain, these are estimates, not exact incidence rates. Regulatory safety information is not a grading basis.
What the
research shows
The grade is C. Product documentation confirms that injected cross-linked hyaluronic acid gel occupies volume, and the pivotal Juvéderm trial found 24-week independent-rated improvement of 1.4 grades versus 0.4 with collagen. Most evidence, however, consists of product-specific manufacturer studies with another filler as the active control, limiting independent conclusions about the magnitude and duration of filler correction in general. The score is 55.
What the
ads claim
An injected gel immediately occupying space does not guarantee a desired facial shape for a fixed duration. Trials show that specific products can lower fold severity for months, while results depend on product, volume, anatomy, and injector technique.
*

Useful facts when choosing a product

  • Filler type was randomized between the two nasolabial folds of the same participant in a split-face comparison.
  • One WSRS grade was the FDA trial responder definition, not a validated between-group minimal important difference.
  • The sites and uses differ completely: 1577 is F 18 points for intra-articular knee injection, and 1849 is D 30 points for intra-articular hip injection; neither is a nasolabial-fold filler verdict.
Gap Measurement · Verdict 1947 · C 55
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

FDA pivotal data enrolled 439 participants in three cohorts of 147, 146, and 146. The 30HV cohort enrolled 146 and assessed 139 at week 24. Filler type was randomized between the two nasolabial folds of the same patient in a split-face comparison. Independent WSRS improvement was 1.4 grades versus 0.4 with collagen, P<0.0001. The manufacturer supported the trial. WSRS reliability and validity were established, but a patient-anchored between-group minimal important difference for one grade was not confirmed.

02

Why this is classified as C (55)

Randomized blinded assessment supports correction through 24 weeks, but small product-specific manufacturer studies with active controls dominate the evidence, giving C with 55 points.

Counterpoint. C does not deny the gel or immediate volume. Rheology, cross-linking, volume, and durability change across products and require product-specific evidence.

Rejudgment record. Cross-check applied — Physical gel volume and 24-week correction were demonstrated, but evidence centers on product-specific manufacturer trials with active comparators

Scoring profile behind this grade
EndpointPPatient-reported treatment goal - the symptom is the goal
ReplicationR2Independently replicated across trials
IndependenceI0Evidence comes only from manufacturer studies
Effect sizeE+Meets the clinically important threshold

The scoring table and the verdict agree (C).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Twelve-week improvement in nasolabial-fold severityCAll three products were noninferior to active collagen, but this was a manufacturer product trial.
Twenty-four-week nasolabial-fold improvement with a specific productCIt was superior to active collagen but came from a manufacturer product trial.
Uniform long-term durability across all hyaluronic-acid fillers?Products and follow-up differ, preventing one universal duration estimate.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1Multicenter double-blind randomized split-face active-controlled trial139Manufacturer device-development study supporting approvalIndependent evaluator improvement on a five-point nasolabial-fold severity scaleAt week 24, 1.4 grades versus 0.4 with cross-linked bovine collagen, P<0.0001Pivotal product-specific active-control evidence
Study 2Systematic review and meta-analysis of randomized nasolabial-fold filler trialsReview authors reported no conflict; many included trials were product-development studiesFold severity, satisfaction, and adverse eventsProduct-specific efficacy was generally supported, but products, comparators, and follow-up varied.Synthesis showing limits to generalization across products
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-08-02).

U.S. Food and Drug Administration. Summary of Safety and Effectiveness Data: JUVEDERM 30, JUVEDERM 24HV, and JUVEDERM 30HV. PMA P050047. 2006.
checked
Cabral LRB, Teixeira LN, Gimenez RP, et al. Tissue Fillers for the Nasolabial Fold Area: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Aesthetic Plast Surg. 2021;45(5):2300-2316. PMID: 34255156. PMCID: PMC8481177.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-02 · Corrections: none

Cite this verdict

Hyaluronic acid filler x nasolabial-fold correction Evidence Grade C card
[Chamgap] Hyaluronic acid filler x nasolabial-fold correction — Evidence Grade C·55. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/hyaluronic-acid-filler-nasolabial-fold-correction/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.